| Emily Mensel, MD | |
|
80 Seymour St, Department Of Traumatology/emergency Medicine, Hartford, CT 06102-8000 | |
| (860) 972-1448 | |
| Not Available |
| Full Name | Emily Mensel |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 80 Seymour St, Hartford, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417360827 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 56459 (Connecticut) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407806391 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000700 |
News Archive
"Aspirin can cause severe damage to both the hard and soft tissues of the mouth," said researchers from the University of Maryland Dental School, Baltimore.
Mylan Inc. today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.
Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.
A treatment billed as a potential breakthrough in the fight against disease, including cancer, could back-fire and make the disease fitter and more damaging, new research has found.
Prostate cancer affects one out of every 6 men during their lifetime and is the second most common cause of cancer-related death for men in the United States, resulting in an estimated 27,500 deaths in 2015. Identifying those men who have a higher risk of developing prostate cancer may reduce mortality.
› Verified 8 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770696643 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000752 |
News Archive
"Aspirin can cause severe damage to both the hard and soft tissues of the mouth," said researchers from the University of Maryland Dental School, Baltimore.
Mylan Inc. today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.
Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.
A treatment billed as a potential breakthrough in the fight against disease, including cancer, could back-fire and make the disease fitter and more damaging, new research has found.
Prostate cancer affects one out of every 6 men during their lifetime and is the second most common cause of cancer-related death for men in the United States, resulting in an estimated 27,500 deaths in 2015. Identifying those men who have a higher risk of developing prostate cancer may reduce mortality.
› Verified 8 days ago
| Entity Name | The Charlotte Hungerford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629075734 PECOS PAC ID: 4486557501 Enrollment ID: O20040128000183 |
News Archive
"Aspirin can cause severe damage to both the hard and soft tissues of the mouth," said researchers from the University of Maryland Dental School, Baltimore.
Mylan Inc. today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.
Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.
A treatment billed as a potential breakthrough in the fight against disease, including cancer, could back-fire and make the disease fitter and more damaging, new research has found.
Prostate cancer affects one out of every 6 men during their lifetime and is the second most common cause of cancer-related death for men in the United States, resulting in an estimated 27,500 deaths in 2015. Identifying those men who have a higher risk of developing prostate cancer may reduce mortality.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Mensel, MD 80 Seymour St, Department Of Traumatology/emergency Medicine, Hartford, CT 06102-8000 Ph: () - | Emily Mensel, MD 80 Seymour St, Department Of Traumatology/emergency Medicine, Hartford, CT 06102-8000 Ph: (860) 972-1448 |
News Archive
"Aspirin can cause severe damage to both the hard and soft tissues of the mouth," said researchers from the University of Maryland Dental School, Baltimore.
Mylan Inc. today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.
Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.
A treatment billed as a potential breakthrough in the fight against disease, including cancer, could back-fire and make the disease fitter and more damaging, new research has found.
Prostate cancer affects one out of every 6 men during their lifetime and is the second most common cause of cancer-related death for men in the United States, resulting in an estimated 27,500 deaths in 2015. Identifying those men who have a higher risk of developing prostate cancer may reduce mortality.
› Verified 8 days ago
Dr. Perry Maxwell Dansky, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Saint Francis Hospital Emergency Department, Hartford, CT 06105 Phone: 860-714-4701 Fax: 860-714-8046 | |
Christina Jennifer Lu, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour Street, Hartford Hospital Department Of Emergency Medicine, Hartford, CT 06102 Phone: 860-972-0001 Fax: 860-545-2274 | |
Dr. Jeffrey Peter Spear, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Emergency Department, Hartford, CT 06105 Phone: 860-714-4001 Fax: 860-714-8046 | |
Jillian Smith, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Dept Of Emergency Medicine, Hartford, CT 06105 Phone: 860-714-4001 | |
Michael W Joseph, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 860-972-1448 Fax: 860-545-1461 | |
Lisa Michelle Samuelson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 860-972-0001 | |
Dr. Rebecca Beth Apollon, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Hartford, CT 06105 Phone: 860-714-4701 Fax: 860-714-8046 |